Results 361 to 370 of about 1,467,646 (404)

A revival of bispecific antibodies

Trends in Biotechnology, 2004
Bispecific antibodies usually do not occur in nature but are constructed by recombinant DNA or cell-fusion technologies. Most are designed to recruit cytotoxic effector cells of the immune system effectively against pathogenic target cells. This complex task explains why, after more than 15 years of extensive research, many different formats of ...
Ralf Lutterbüse, Patrick A. Baeuerle, Peter Kufer   +2 more
openaire   +3 more sources

Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-cMet Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC.

Cancer Discovery, 2020
EGFR exon 20 insertion driver mutations (Exon20ins) in NSCLC are insensitive to EGFR-TKIs. Amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR/cMet, has shown preclinical activity in TKI-sensitive EGFR-mutated NSCLC models and in an ongoing ...
J. Yun, Soo-Hwan Lee, Seok-Young Kim, Seonhyang Jeong, Jae-Hwan Kim, K. Pyo, Chaewon Park, S. Heo, M. Yun, Sangbin Lim, S. Lim, M. Hong, H. R. Kim, M. Thayu, J. Curtin, R. Knoblauch, M. V. Lorenzi, A. Roshak, B. Cho   +18 more
semanticscholar   +1 more source

Pharmacokinetics of Bispecific Antibody

Current Pharmacology Reports, 2017
This article provides a brief overview of bispecific antibody (BsAb) mechanisms of action, structures, and pharmacokinetic (PK) properties, including absorption, distribution, and elimination. Recent trend in BsAb development is also introduced from a PK perspective.
Yang Chen, Yan Xu
openaire   +2 more sources

Immunotherapeutic perspective for bispecific antibodies

Immunology Today, 2000
Bispecific antibodies (BsAb) can, by virtue of combining two binding specificities, improve the selectivity and efficacy of antibody-based treatment of human disease. Recent studies underline the importance of both the 'anti-trigger' and 'anti-target' modalities of BsAb for therapeutic efficacy.
Annemiek B. van Spriel, Heidi H. van Ojik, Jan G. J. van de Winkel   +2 more
openaire   +3 more sources

Catumaxomab: A bispecific trifunctional antibody

Drugs of Today, 2009
The trifunctional bispecific monoclonal antibody catumaxomab has two binding specificities directed at epithelial cell adhesion molecule (EpCAM) and the T-cell antigen CD3. With its Fc-fragment, catumaxomab additionally binds accessory cells such as dendritic cells, macrophages and natural killer cells.
Marcus Schmidt, Andreas Kuemmel, Martin Sebastian, Alexander Schmittel   +3 more
openaire   +3 more sources

Glofitamab CD20-TCB bispecific antibody

Leukemia and Lymphoma, 2021
Bispecific T-cell recruiting antibodies are emerging as a potent immunotherapeutic class in the treatment of B-cell malignancies and act by simultaneously targeting antigens on T-cells and malignant cells to effect tumor cell death. Glofitamab is a novel
A. Minson, M. Dickinson
semanticscholar   +1 more source

Efficacy and safety of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MM).

, 2021
8006Background: Elranatamab (PF-06863135) is a humanized bispecific monoclonal antibody (IgG2a) that targets BCMA, a member of the tumor necrosis factor receptor superfamily expressed in MM, and CD...
N. Bahlis, N. Raje, C. Costello, B. Dholaria, M. Solh, M. Levy, M. Tomasson, H. Dube, Feng Liu, K. Liao, C. Basu, A. Skoura, E. Chan, S. Trudel, A. Jakubowiak, M. Chu, C. Gasparetto, A. Dalovisio, M. Sebag, A. Lesokhin   +19 more
semanticscholar   +1 more source

Bispecific antibodies for delivery into the brain

Current Opinion in Chemical Biology, 2013
The blood-brain barrier (BBB) is a formidable obstacle preventing drug delivery to the brain, particularly for large protein therapeutics. The utilization of endogenous brain endothelial transport pathways, however, represents a promising approach to cross the cellular barrier through receptor-mediated transcytosis.
Ryan J. Watts, Mark S. Dennis
openaire   +3 more sources

Targeting cancer with bispecific antibodies [PDF]

Science, 2021
Bispecific antibodies might provide off-the-shelf immunotherapeutics for treating ...
openaire   +2 more sources

Bispecific antibodies for the treatment of hemophilia A

Expert Opinion on Biological Therapy, 2021
Emicizumab is a bispecific antibody exerting cofactor function of FVIIIa irrespective of the presence of FVIII inhibitors. Long-term data of phase 1/2 and phase 3 studies have been accumulated. Various questions such as indicated patients, ITI, application to PUPs, hemostatic treatment including surgeries, and emicizumab-related morbidity remain to be ...
openaire   +3 more sources